Clinical data | |
---|---|
Trade names | Diabeta, Glynase, Micronase, others[1] |
Other names | Glyburide (USAN US) |
AHFS/Drugs.com | Monograph |
MedlinePlus | a684058 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | Extensive |
Metabolism | Liver hydroxylation (CYP2C9-mediated) |
Elimination half-life | 10 hours |
Excretion | Kidney and bile duct |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.030.505 |
Chemical and physical data | |
Formula | C23H28ClN3O5S |
Molar mass | 494.00 g·mol−1 |
3D model (JSmol) | |
Melting point | 169 to 170 °C (336 to 338 °F) |
| |
| |
(verify) |
Glibenclamide, also known as glyburide, is an antidiabetic medication used to treat type 2 diabetes.[1] It is recommended that it be taken together with diet and exercise.[1] It may be used with other antidiabetic medication.[1] It is not recommended for use by itself in type 1 diabetes.[1] It is taken by mouth.[1]
Common side effects include nausea and heartburn.[1] Serious side effects may include angioedema and low blood sugar.[1] It is generally not recommended during pregnancy but can be used during breastfeeding.[3] It is in the sulfonylureas class of medications and works by increasing the release of insulin from the pancreas.[1]
Glibenclamide was discovered in 1969 and approved for medical use in the United States in 1984.[4][1] It is available as a generic medication.[3] In 2021, it was the 214th most commonly prescribed medication in the United States, with more than 2 million prescriptions.[5][6]